Are Two Doses of Human Papillomavirus Vaccine Sufficient for Girls Aged 15-18 Years? Results from a Cohort Study in India

Overview

Journal Papillomavirus Res

Specialties Microbiology
Oncology

Date 2018 Mar 27

PMID 29578097

Citations 13

Authors

Neerja Bhatla

Bhagwan M Nene

Smita Joshi

Pulikottil O Esmy

Usha Rani Reddy Poli

Geeta Joshi

Yogesh Verma

Eric Zomawia

Sharmila Pimple

Priya R Prabhu

Partha Basu

Richard Muwonge

Sanjay Hingmire

Catherine Sauvaget

Eric Lucas

Michael Pawlita

Tarik Gheit

Kasturi Jayant

Sylla G Malvi

Maqsood Siddiqi

Angelika Michel

Julia Butt

Subha Sankaran

Thiraviam Pillai Rameshwari Ammal Kannan

Rintu Varghese

Uma Divate

Martina Willhauck-Fleckenstein

Tim Waterboer

Martin Muller

Peter Sehr

Alka Kriplani

Gauravi Mishra

Radhika Jadhav

Ranjit Thorat

Massimo Tommasino

M Radhakrishna Pillai

Rengaswamy Sankaranarayanan

Affiliations

Soon will be listed here.

Abstract

Extending two-dose recommendations of HPV vaccine to girls between 15 and 18 years will reduce program cost and improve compliance. Immunogenicity and vaccine targeted HPV infection outcomes were compared between 1795 girls aged 15-18 years receiving two (1-180 days) and 1515 girls of same age receiving three (1-60-180 days) doses. Immunogenicity outcomes in 15-18 year old two-dose recipients were also compared with the 10-14 year old three-dose (N = 2833) and two-dose (N = 3184) recipients. The 15-18 year old two-dose recipients had non-inferior L1-binding antibody titres at seven months against vaccine-targeted HPV types compared to three-dose recipients at 15-18 years and three-dose recipients at 10-14 years of age. Neutralizing antibody titres at 18 months in 15-18 year old two-dose recipients were non-inferior to same age three-dose recipients for all except HPV 18. The titres were inferior to those in the 10-14 year old three-dose recipients for all targeted types. Frequency of incident infections from vaccine-targeted HPV types in the 15-18 year old two-dose recipients was similar to the three dose recipients. None of the girls receiving two or three doses had persistent infection from vaccine-targeted types. These findings support that two doses of HPV vaccine can be extended to girls aged 15-18 years.

Citing Articles

Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccine.

Bhatla N, Muwonge R, Malvi S, Joshi S, Poli U, Lucas E Hum Vaccin Immunother. 2023; 19(3):2289242.

PMID: 38078840 PMC: 10760374. DOI: 10.1080/21645515.2023.2289242.

Different dose series of human papillomavirus vaccine in young females: a pair-wise meta-analysis and network meta-analysis from randomized controlled trials.

Kemin L, Mengpei Z, Jing Z, Rutie Y Front Public Health. 2023; 11:1152057.

PMID: 37808981 PMC: 10552866. DOI: 10.3389/fpubh.2023.1152057.

Stated preferences for human papillomavirus vaccination for adolescents in selected communities in Ibadan, Southwest Nigeria: A discrete choice experiment.

Balogun F, Omotade O, Svensson M Hum Vaccin Immunother. 2022; 18(6):2124091.

PMID: 36383765 PMC: 9746423. DOI: 10.1080/21645515.2022.2124091.

Humans with inherited T cell CD28 deficiency are susceptible to skin papillomaviruses but are otherwise healthy.

Beziat V, Rapaport F, Hu J, Titeux M, Bonnet des Claustres M, Bourgey M Cell. 2021; 184(14):3812-3828.e30.

PMID: 34214472 PMC: 8329841. DOI: 10.1016/j.cell.2021.06.004.

Experience of Human Papillomavirus Vaccination Project in a Community Set Up-An Indian Study.

Mandal R, Banerjee D, Gupta K, Chatterjee P, Vernekar M, Ray C Asian Pac J Cancer Prev. 2021; 22(3):699-704.

PMID: 33773531 PMC: 8286678. DOI: 10.31557/APJCP.2021.22.3.699.

References

Day P, Kines R, Thompson C, Jagu S, Roden R, Lowy D . In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe. 2010; 8(3):260-70. PMC: 2939057. DOI: 10.1016/j.chom.2010.08.003. View

Block S, Nolan T, Sattler C, Barr E, Giacoletti K, Marchant C . Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006; 118(5):2135-45. DOI: 10.1542/peds.2006-0461. View

Lehtinen M, Paavonen J, Wheeler C, Jaisamrarn U, Garland S, Castellsague X . Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2011; 13(1):89-99. DOI: 10.1016/S1470-2045(11)70286-8. View

Waterboer T, Sehr P, Michael K, Franceschi S, Nieland J, Joos T . Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem. 2005; 51(10):1845-53. DOI: 10.1373/clinchem.2005.052381. View

Michael K, Waterboer T, Sehr P, Rother A, Reidel U, Boeing H . Seroprevalence of 34 human papillomavirus types in the German general population. PLoS Pathog. 2008; 4(6):e1000091. PMC: 2408730. DOI: 10.1371/journal.ppat.1000091. View

Sankaranarayanan R, Prabhu P, Pawlita M, Gheit T, Bhatla N, Muwonge R . Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol. 2015; 17(1):67-77. PMC: 5357737. DOI: 10.1016/S1470-2045(15)00414-3. View

Smith J, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R . Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007; 121(3):621-32. DOI: 10.1002/ijc.22527. View

Zur Hausen H . Papillomaviruses in the causation of human cancers - a brief historical account. Virology. 2009; 384(2):260-5. DOI: 10.1016/j.virol.2008.11.046. View

Lowy D . HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions. J Clin Invest. 2016; 126(1):5-11. PMC: 4701560. DOI: 10.1172/JCI85446. View

10.

Bhatla N, Suri V, Basu P, Shastri S, Datta S, Bi D . Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women. J Obstet Gynaecol Res. 2010; 36(1):123-32. DOI: 10.1111/j.1447-0756.2009.01167.x. View

11.

Erickson B, Landers E, Huh W . Update on vaccination clinical trials for HPV-related disease. Clin Ther. 2014; 36(1):8-16. DOI: 10.1016/j.clinthera.2013.11.003. View

12.

Schiller J, Lowy D . Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol. 2012; 10(10):681-92. PMC: 6309166. DOI: 10.1038/nrmicro2872. View

13.

Dillner J, Kjaer S, Wheeler C, Sigurdsson K, Iversen O, Hernandez-Avila M . Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010; 341:c3493. PMC: 2907480. DOI: 10.1136/bmj.c3493. View

14.

Kines R, Thompson C, Lowy D, Schiller J, Day P . The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc Natl Acad Sci U S A. 2009; 106(48):20458-63. PMC: 2787115. DOI: 10.1073/pnas.0908502106. View

15.

Bosch F, Broker T, Forman D, Moscicki A, Gillison M, Doorbar J . Comprehensive control of human papillomavirus infections and related diseases. Vaccine. 2013; 31 Suppl 5:F1-31. DOI: 10.1016/j.vaccine.2013.10.001. View

16.

Li N, Franceschi S, Howell-Jones R, Snijders P, Clifford G . Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer. 2010; 128(4):927-35. DOI: 10.1002/ijc.25396. View

17.

Sehr P, Rubio I, Seitz H, Putzker K, Ribeiro-Muller L, Pawlita M . High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses. PLoS One. 2013; 8(10):e75677. PMC: 3790823. DOI: 10.1371/journal.pone.0075677. View

18.

Romanowski B, Schwarz T, Ferguson L, Peters K, Dionne M, Schulze K . Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011; 7(12):1374-86. PMC: 3338934. DOI: 10.4161/hv.7.12.18322. View

19.

Pedersen C, Petaja T, Strauss G, Rumke H, Poder A, Richardus J . Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007; 40(6):564-71. DOI: 10.1016/j.jadohealth.2007.02.015. View

20.

Schiller J, Castellsague X, Garland S . A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012; 30 Suppl 5:F123-38. PMC: 4636904. DOI: 10.1016/j.vaccine.2012.04.108. View